Postpartum Depression Treatment: Therapy, Drugs and Timelines

Postpartum depression treatment usually means psychotherapy, antidepressant medication, or both, according to the National Institute of Mental Health, which names cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) as the evidence-based therapies^[7]. Two newer drugs approved specifically for postpartum depression, brexanolone and zuranolone, work on GABA-A receptors: brexanolone mimics the neurosteroid allopregnanolone, and zuranolone acts through similar mechanisms^[4].

This guide covers how each option works, what the trials found and how long treatment takes. How common postpartum depression is, by state and group, is tracked on our postpartum depression data page and the postpartum population overview.

The American College of Obstetricians and Gynecologists (ACOG) recommends in its 2023 guideline that obstetricians start medication for perinatal depression, refer patients to behavioral health care, or both^[8]. NIMH notes that women with postpartum depression generally will not feel better without treatment^[7].

Therapy is the most studied non-drug treatment. A 2025 systematic review in the Annals of Internal Medicine, funded by the Agency for Healthcare Research and Quality, pooled 44 randomized trials of psychological therapies for depression during pregnancy and up to 1 year postpartum^[1].

Cognitive behavioral therapy (25 trials, 2,962 participants) probably reduced depressive symptoms more than usual care, by an average 1.7 points on the 30-point Edinburgh Postnatal Depression Scale (EPDS), and may raise recovery rates (relative risk 1.7)^[1]. Interpersonal therapy (9 trials, 1,003 participants) showed the same 1.7-point average reduction, also with moderate strength of evidence^[1].

Behavioral activation may reduce symptoms by 1.5 points versus usual care (3 trials, 508 participants, low strength of evidence)^[1]. General counseling did not clearly outperform usual care in 3 trials with 247 participants^[1].

The authors flagged limits: participants could not be blinded to their treatment, and the differences "may not be clinically important"^[1].

What postpartum depression counseling involves

In CBT, people learn to challenge and change unhelpful thoughts and behaviors. IPT focuses on communication within relationships, building support networks and setting realistic expectations^[7].

ACOG says therapy may be one-on-one, in a group, or with a partner or family, and may last a few weeks or a few months or longer^[10]. The wider evidence base outside the perinatal period is covered in cognitive behavioral therapy for depression.

Selective serotonin reuptake inhibitors (SSRIs) are the most studied antidepressants for postpartum depression. A 2021 Cochrane review found 11 randomized trials with 1,016 women, most testing SSRIs for 4 to 12 weeks^[2].

Pooled results suggested a benefit over placebo at 5 to 12 weeks: 55% of women on an SSRI responded versus 43% on placebo, and 42% reached remission versus 27%^[2]. The review graded this evidence low or very low certainty because the trials were few and small, with high dropout^[2].

Dropout was 27% in both groups, and there was too little evidence to say whether antidepressants outperform therapy head to head^[2]. NIMH says antidepressants usually take 4 to 8 weeks to work, and ACOG patient guidance says it may take 3 to 4 weeks before a person starts to feel better^[7][10].

Antidepressants and breastfeeding

Antidepressants pass into breast milk, though ACOG says the levels found are generally very low^[10]. The Cochrane authors found limited data on breastfed infants and noted no adverse effects in the trials that reported on them^[2].

ACOG recommends against withholding or discontinuing mental health medications because of pregnancy or lactation status alone^[8]. Prescribing patterns are covered in antidepressant usage statistics.

Brexanolone mimics allopregnanolone, increasing the inhibitory actions of GABA-A receptors, and zuranolone acts via similar mechanisms^[4]. NIMH says this appears to work differently from traditional antidepressants^[7].

Zuranolone (Zurzuvae)

The FDA approved zuranolone on August 4, 2023, as the first oral medication for postpartum depression in adults; the dose is 50 mg once daily in the evening with a fatty meal for 14 days^[3]. Approval rested on two placebo-controlled trials with 345 patients whose symptoms began in the third trimester or within 4 weeks of delivery^[9][3].

In the 50 mg trial, scores on the 17-item Hamilton Depression Rating Scale (HAMD-17) fell 15.6 points by day 15 versus 11.6 on placebo, a 4.0-point difference^[9]. The effect was still present at day 42, four weeks after the last dose^[3].

The label carries a boxed warning against driving or operating heavy machinery for at least 12 hours after a dose^[3]. Somnolence affected 36% of zuranolone patients versus 6% on placebo in the 50 mg trial^[9].

The drug may cause suicidal thoughts and fetal harm, and the FDA advises contraception during treatment and for 1 week after^[3]. Zuranolone passes into breast milk with unclear effects on infants; ACOG describes either continuing to breastfeed during the 14 days or pausing until 1 week after the last dose^[10].

Brexanolone (Zulresso)

Brexanolone became the first drug approved for postpartum depression in March 2019^[4]. It is given as a continuous IV infusion over 60 hours (2.5 days), with a health care provider on site throughout and continuous pulse oximetry^[5].

A boxed warning covers excessive sedation and sudden loss of consciousness, so the drug is available only through a restricted REMS program, and patients must be accompanied during interactions with their children^[5]. The most common side effects in trials were sedation, dry mouth, loss of consciousness and flushing^[5].

Timelines differ sharply by treatment: brexanolone runs 60 hours^[5], zuranolone 14 days with effects measured at day 15^[3], and standard antidepressants usually need 4 to 8 weeks to work^[7]. Therapy may last a few weeks to a few months or longer^[10].

ACOG recommends using a validated screening tool to track response and remission, and raising the medication dose when clinically indicated, with remission as the goal^[8].

Symptoms can persist well past the newborn period. An NIH study that followed about 5,000 mothers in New York State found roughly 1 in 4 had high depressive symptoms at some point in the 3 years after giving birth^[11].

That study used a 5-item screening questionnaire rather than a clinical diagnosis, and its authors suggested screening for at least 2 years after childbirth instead of stopping at 6 months^[11]. The baby blues, by contrast, usually ease within a few days to 2 weeks without treatment^[10].

The U.S. Preventive Services Task Force gives a grade B recommendation for counseling, mainly CBT or IPT, for pregnant and postpartum people at increased risk of perinatal depression^[12]. Risk factors it lists include a history of depression, current symptoms below the diagnostic threshold, low income, adolescent or single parenthood, and recent intimate partner violence^[12].

The task force found limited or mixed evidence for physical activity, education, medication, dietary supplements and health system programs as prevention^[12]. ACOG notes that people with a history of depression may be advised to begin treatment right after birth to prevent a postpartum episode^[10].

Postpartum psychosis is a separate condition involving delusions, hallucinations, mania, paranoia or confusion. NIMH classifies it as a psychiatric emergency that requires hospitalization^[7].

Treatment depends on detection first. In CDC data from 31 Pregnancy Risk Assessment Monitoring System sites in 2018, 13.2% of women with a recent live birth reported postpartum depressive symptoms^[6]. Symptoms were self-reported on a survey taken about 4 months after birth and are not a clinical diagnosis^[6].

One in five women said no provider asked about depression during prenatal visits, and one in eight were not asked at postpartum visits^[6]. The share asked during prenatal care ranged from 51.3% in Puerto Rico to 90.7% in Alaska^[6].

ACOG's guideline calls for treatment of perinatal mood and anxiety disorders to be equitably available and accessible to all pregnant and postpartum individuals^[8]. State-by-state rates are on the postpartum depression pillar, with more context in postpartum depression statistics and maternal mental health statistics.